期刊
CNS SPECTRUMS
卷 20, 期 2, 页码 112-121出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852914000078
关键词
ADHD; diagnosis; functional impairment; Lifetime Impairment Survey; treatment
资金
- Shire
- Janssen-Cilag
- Vifor
- QBTech
- Flynn Pharma
- Eli Lilly
- Akili Interactive Labs
- Alcobra
- VAYA Pharma
- SynapDx
- National Institutes of Health (NIH)
- Otsuka
- McNeil
- Janssen
- Novartis
- Pfizer
- Medice
- German Research Foundation
- German Ministry of Education and Research
- Medical Research Council [G9817803B] Funding Source: researchfish
Introduction. The Lifetime Impairment Survey, conducted in Europe, assessed impairment and symptoms of attentiondeficit/ hyperactivity disorder (ADHD) in childhood, and experiences of ADHD diagnosis and treatment, as recalled by adults. Methods. Adults with ADHD and without ADHD (control group) were invited to participate in an internet-based survey and report on their childhood experiences. History of ADHD diagnosis was self-reported. Groups were compared using impairment and symptom scales. Results. Overall, 588 adults with ADHD and 736 without ADHD participated. Mean (standard deviation [SD]) age at diagnosis of ADHD was 20.0 (12.6) years (median 18.0) following consultation with 3.8 (5.1) doctors (median 2) over 44.6 (69.3) months (median 17.0). A total of 64.1% (377/588) of adults with ADHD reported frustration or difficulties during the diagnostic process. The ADHD group had a higher mean (SD) score versus control for general (3.3 [1.2] vs 2.1 [1.2]; p<0.001) and school impairment (2.8 [0.7] vs 2.3 [0.6]; p < 0.001) but not home impairment (2.1 [0.5] for both groups). Discussion. The survey demonstrated that ADHD had a negative impact on all aspects of childhood investigated, as recalled by adults. Conclusions. These data provide insights into childhood impairments and identify areas for improvement in the management and treatment of ADHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据